See what’s new.
Gene therapy developed at Duke to be commercialized by a local biotechnology company
A universal gene editing therapy for Pompe disease, invented in the lab of Duke Professor Dwight Koeberl, is licensed for further development by local start-up GeneVentiv.
GeneVentiv Announces Global Licensing Agreement for Universal Gene Editing Therapy for Infantile Onset and Late Onset Pompe Disease
GeneVentiv Therapeutics, a Raleigh-based gene therapy company, has taken an exclusive license to Pompe disease gene editing technology developed in the lab of Professor Dwight Koeberl (Pediatrics, SOM).
Fellow Turned Inventor Gives Glaucoma Care an Upgrade
While Gabriel and Challa iterated on the new and improved GDD, they also tapped into Duke’s innovation ecosystem resources and connected with Duke’s Office for Translation & Commercialization (OTC), Duke’s tech transfer office.
VQ Biomedical secures $5M, including a seed round led by Harbright, WIN, and DCP
VQ Biomedical is a Duke University start-up and DCP portfolio company resulting from the collaboration Duke clinicians and engineers.
Breath of Life: Duke Inventors Secure $5M for Novel Oxygenation Startup
Duke clinician partners with Duke engineers to tackle an elusive critical care challenge: Can oxygen be delivered directly into the bloodstream through a catheter?
Colleagues off the Court: Duke and UNC Champion Research and Innovation on Capitol Hill
From Google’s search to 3D printing, from MRIs to mRNA vaccines, countless products and services that make our lives better started as university born innovations from research.
Duke University ranks 24th worldwide for patents granted to academic institutions
Duke researchers are pioneering inventors and Duke is successfully commercializing these inventions for the benefit of the public.
Donald Patrick McDonnell, PhD, Wins 2025 Baxter Prize for Entrepreneurship
Professor Donald McDonnell (PCB, SOM) is a serial inventor with multiple commercialized technologies, including FDA-approved breast cancer drug ORSERDU.
Duke Translational Chaperones help researchers secure over $6.5M in translational funding
In their pilot year, the new team at OTC worked with Duke life sciences PIs to position their research for maximal translational impact. Who will they help next?